Strong pooled Ph III safety data for Amgen's Vectibix
US biotechnology major Amgen has reported strong interim pooled, blinded, safety results from two Phase III trials evaluating Vectibix (panitumumab) in combination with standard chemotherapy in earlier lines of metastatic colorectal cancer. Updated data from these trials, as well as the first prospective evaluation of the impact of the clinical biomarker KRAS on Vectibix efficacy in combination with chemotherapy, were presented at the 2008 American Society of Clinical Oncology's annual meeting in Chicago.
The PRIME study is a global, Phase III trial investigating Vectibix in combination with FOLFOX chemotherapy as first-line treatment for mCRC among wild-type KRAS and all randomized patients. Final enrollment was completed in February 2008 with a total of 1,183 patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze